AR088250A1 - Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide - Google Patents
Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioideInfo
- Publication number
- AR088250A1 AR088250A1 ARP120103721A ARP120103721A AR088250A1 AR 088250 A1 AR088250 A1 AR 088250A1 AR P120103721 A ARP120103721 A AR P120103721A AR P120103721 A ARP120103721 A AR P120103721A AR 088250 A1 AR088250 A1 AR 088250A1
- Authority
- AR
- Argentina
- Prior art keywords
- opioid
- dosage form
- pharmaceutical dosage
- opioid antagonist
- opioid agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Abstract
La presente se refiere a una forma de dosificación farmacéutica para administración oral que tiene una resistencia a rompimiento de al menos 300 N y que comprende un agonista opioide, un antagonista opioide, y un óxido de polialquileno que tiene un peso molecular promedio de al menos 200,000 g/mol, en donde de acuerdo con Ph. Eur. el perfil de liberación in vitro del agonista opioide esencialmente corresponde al perfil de liberación in vitro del antagonista opioide, y en donde el agonista opioide y el antagonista opioide se mezclan íntimamente entre sí y se mezclan de manera homogénea en el óxido de polialquileno. Reivindicación 12: La forma de dosificación farmacéutica de acuerdo a cualquiera de las reivindicaciones precedentes, en donde el agonista opioide es oxicodona o una sal fisiológicamente aceptable de la misma. Reivindicación 13: La forma de dosificación farmacéutica de acuerdo a cualquiera de las reivindicaciones precedentes, en donde el antagonista opioide se selecciona del grupo que consiste de naltrexona, naloxona, nalmefeno, ciclazacina, levalorfano, sales farmacéuticamente aceptables de los mismos y mezclas de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11008131 | 2011-10-06 | ||
EP11009090 | 2011-11-16 | ||
EP12001297 | 2012-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR088250A1 true AR088250A1 (es) | 2014-05-21 |
Family
ID=47018994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120103721A AR088250A1 (es) | 2011-10-06 | 2012-10-05 | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide |
Country Status (18)
Country | Link |
---|---|
US (1) | US20130090349A1 (es) |
EP (1) | EP2763664A2 (es) |
JP (1) | JP2014528437A (es) |
KR (1) | KR20140075704A (es) |
CN (1) | CN103998025A (es) |
AR (1) | AR088250A1 (es) |
AU (1) | AU2012320496C1 (es) |
BR (1) | BR112014008120A2 (es) |
CA (1) | CA2850853A1 (es) |
CL (1) | CL2014000361A1 (es) |
CO (1) | CO6950467A2 (es) |
EA (1) | EA029508B1 (es) |
EC (1) | ECSP14013269A (es) |
HK (1) | HK1200741A1 (es) |
IL (1) | IL230819A0 (es) |
MX (1) | MX2014003973A (es) |
PE (1) | PE20141171A1 (es) |
WO (1) | WO2013050539A2 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
ES2360102T3 (es) | 2003-03-26 | 2011-05-31 | Egalet A/S | Sistema para la liberación controlada de morfina. |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
MX2010008138A (es) | 2008-01-25 | 2010-08-10 | Gruenenthal Gmbh | Forma de dosis farmaceutica. |
RU2508092C2 (ru) | 2008-05-09 | 2014-02-27 | Грюненталь Гмбх | Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки |
EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
AR077493A1 (es) | 2009-07-22 | 2011-08-31 | Gruenenthal Gmbh | Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion |
WO2011009604A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
NZ603170A (en) | 2010-05-10 | 2015-04-24 | Euro Celtique Sa | Combination of active loaded granules with additional actives |
JP5838199B2 (ja) | 2010-05-10 | 2016-01-06 | ユーロ−セルティーク エス.エイ. | 活性剤を含まない顆粒およびその顆粒を含む錠剤の製造 |
WO2012028319A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
AR082862A1 (es) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
KR20140053159A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
NO2736497T3 (es) | 2011-07-29 | 2018-01-20 | ||
JP6085307B2 (ja) * | 2011-11-17 | 2017-02-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 薬理学的に活性な成分、オピオイドアンタゴニストおよび/または嫌忌剤(aversiveagent)、ポリアルキレンオキシドおよび陰イオン性ポリマーを含むタンパーレジスタント経口医薬剤形 |
WO2013127831A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
PT2838512T (pt) | 2012-04-18 | 2018-11-09 | Gruenenthal Gmbh | Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping) |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
CA2881144A1 (en) * | 2012-11-09 | 2014-05-09 | Purdue Pharma | Pharmaceutical compositions comprising hydromorphone and naloxone |
BR112015026549A2 (pt) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | forma de dosagem à prova de violação contendo uma ou mais partículas |
AR096439A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido que contiene una o más partículas |
KR20160031526A (ko) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형 |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
MX2016006279A (es) | 2013-11-13 | 2016-09-07 | Euro Celtique Sa | Hidromorfona y naloxona para el tratamiento del dolor y el sindrome de disfuncion intestinal opiacea. |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
EP3079661B1 (de) | 2013-12-11 | 2021-05-05 | Algobate AG | Naloxon-monopräparat und mehrschichttablette |
US10105360B2 (en) | 2013-12-11 | 2018-10-23 | Develco Pharma Schweiz Ag | Method and composition for the treatment of opioid induced constipation |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CA2929866A1 (en) * | 2013-12-23 | 2015-07-02 | Purdue Pharma L.P. | Opioid antagonist formulations |
CA2847781C (en) * | 2014-03-28 | 2019-03-12 | Purdue Pharma | Reducing drug liking in a subject |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
WO2016091805A2 (de) * | 2014-12-08 | 2016-06-16 | Develco Pharma Schweiz Ag | Naloxon-monopräparat und mehrschichttablette |
US20160310428A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
WO2016170093A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
CA2983634A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from particles |
AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US9861629B1 (en) | 2015-10-07 | 2018-01-09 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
EP3290027A1 (en) * | 2016-09-02 | 2018-03-07 | Develco Pharma Schweiz AG | Method and composition for the treatment of opioid induced constipation |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19710008A1 (de) * | 1997-03-12 | 1998-09-17 | Basf Ag | Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung |
AU2002316738B2 (en) * | 2001-07-18 | 2009-01-08 | Euro-Celtique S.A. | Pharmaceutical combinations of oxycodone and naloxone |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
AU2002321879A1 (en) | 2001-08-06 | 2003-03-03 | Thomas Gruber | Pharmaceutical formulation containing dye |
JP4620355B2 (ja) | 2002-04-05 | 2011-01-26 | ユーロ−セルティーク エス.エイ. | 活性化合物の持続、不変及び独立放出のためのマトリクス |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
KR20120104199A (ko) | 2003-08-06 | 2012-09-20 | 그뤼넨탈 게엠베하 | 남용 방지 제형 |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
PL1740156T3 (pl) | 2004-04-22 | 2011-12-30 | Gruenenthal Gmbh | Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej |
BRPI0513300B1 (pt) | 2004-07-01 | 2018-11-06 | Gruenenthal Gmbh | forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol |
EP1765298B1 (de) | 2004-07-01 | 2012-10-24 | Gruenenthal Gmbh | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders |
CA2572491A1 (en) | 2004-07-01 | 2006-01-12 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse |
ATE396703T1 (de) * | 2004-07-27 | 2008-06-15 | Unilever Nv | Haarpflegezusammensetzungen |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20060194759A1 (en) * | 2005-02-25 | 2006-08-31 | Eidelson Stewart G | Topical compositions and methods for treating pain and inflammation |
EP1991207A2 (en) * | 2006-01-21 | 2008-11-19 | Abbott GmbH & Co. KG | Dosage form and method for the delivery of drugs of abuse |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
CN102216461B (zh) | 2008-07-31 | 2015-05-13 | 英荷谷物有限公司 | 抗除草剂的向日葵植物 |
GB0909680D0 (en) * | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
WO2011009604A1 (en) * | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
-
2012
- 2012-10-05 BR BR112014008120A patent/BR112014008120A2/pt not_active IP Right Cessation
- 2012-10-05 MX MX2014003973A patent/MX2014003973A/es unknown
- 2012-10-05 KR KR1020147009106A patent/KR20140075704A/ko not_active Application Discontinuation
- 2012-10-05 WO PCT/EP2012/069735 patent/WO2013050539A2/en active Application Filing
- 2012-10-05 US US13/645,595 patent/US20130090349A1/en not_active Abandoned
- 2012-10-05 JP JP2014533921A patent/JP2014528437A/ja active Pending
- 2012-10-05 EP EP12772756.8A patent/EP2763664A2/en not_active Withdrawn
- 2012-10-05 CA CA2850853A patent/CA2850853A1/en not_active Abandoned
- 2012-10-05 AU AU2012320496A patent/AU2012320496C1/en not_active Ceased
- 2012-10-05 CN CN201280049146.4A patent/CN103998025A/zh active Pending
- 2012-10-05 PE PE2014000279A patent/PE20141171A1/es not_active Application Discontinuation
- 2012-10-05 AR ARP120103721A patent/AR088250A1/es unknown
- 2012-10-05 EA EA201400413A patent/EA029508B1/ru not_active IP Right Cessation
-
2014
- 2014-02-05 IL IL230819A patent/IL230819A0/en unknown
- 2014-02-12 CO CO14029690A patent/CO6950467A2/es not_active Application Discontinuation
- 2014-02-13 CL CL2014000361A patent/CL2014000361A1/es unknown
- 2014-03-25 EC ECSP14013269 patent/ECSP14013269A/es unknown
-
2015
- 2015-02-11 HK HK15101501.3A patent/HK1200741A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2012320496B2 (en) | 2017-05-18 |
JP2014528437A (ja) | 2014-10-27 |
BR112014008120A2 (pt) | 2017-04-11 |
CN103998025A (zh) | 2014-08-20 |
IL230819A0 (en) | 2014-03-31 |
HK1200741A1 (en) | 2015-08-14 |
WO2013050539A2 (en) | 2013-04-11 |
AU2012320496C1 (en) | 2017-09-28 |
EA029508B1 (ru) | 2018-04-30 |
EP2763664A2 (en) | 2014-08-13 |
ECSP14013269A (es) | 2014-12-30 |
PE20141171A1 (es) | 2014-09-21 |
KR20140075704A (ko) | 2014-06-19 |
AU2012320496A1 (en) | 2014-02-13 |
CL2014000361A1 (es) | 2014-06-20 |
NZ620252A (en) | 2015-09-25 |
US20130090349A1 (en) | 2013-04-11 |
CO6950467A2 (es) | 2014-05-20 |
EA201400413A1 (ru) | 2014-11-28 |
MX2014003973A (es) | 2014-05-07 |
CA2850853A1 (en) | 2013-04-11 |
WO2013050539A3 (en) | 2013-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR088250A1 (es) | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide | |
PE20141671A1 (es) | Forma de dosis farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o repelente opioide, oxido de polialquileno y un polimero anionico | |
BR112016001678A2 (pt) | Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária | |
EA201400246A1 (ru) | Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости | |
AR089130A1 (es) | FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO | |
CL2013001943A1 (es) | Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma. | |
MX2012012277A (es) | Compuestos organicos. | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
AR088232A1 (es) | Composiciones farmaceuticas | |
NZ709958A (en) | Enhanced stability of novel liquid compositions | |
BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
AR085173A1 (es) | Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas | |
CO6341547A2 (es) | Uso de antagonistas opioides para el tratamiento de retencion urinaria | |
CY1119328T1 (el) | Αναστολεας ανοχης σε αναλγητικα | |
MX347105B (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona. | |
EA201171271A1 (ru) | Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида | |
CL2013003700A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico. | |
MX2012001691A (es) | Composiciones de linaclotida que se desintegran oralmente. | |
MX2012011216A (es) | Antagonista del receptor opioide para usarse en el tratamiento de la enfermedad herpes zóster. | |
EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол | |
GT201400042A (es) | Compuesto de benzotiazolona | |
EA201291014A1 (ru) | Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция | |
PE20142444A1 (es) | Nueva composicion de alfentanilo para el tratamiento del dolor agudo | |
SI2729474T1 (en) | (TIENO (2,3-b) (1,5) BENZOXAZEPIN-4-YL) PIPERAZINE-1-IL COMPOUNDS AS TWO ACTIVE H1 INVERTIVE AGENTS / 5-HT2A ANTAGONISTS | |
CY1119701T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει υδροχλωρικη βαρδεναφιλη |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |